Effect of ibanphosphate combined with chemotherapy on inflammatory factors and bone metabolism indicators in non-small cell lung cancer patients with bone metastasis

  Objective  To investigate the effect of ibanphosphate combined with chemotherapy on inflammatory factors and bone metabolism indicators in non-small cell lung cancer(NSCLC) patients with bone metastasis.

  Methods  A total of 120 NSCLC patients with bone metastasis were included in this study. Patients with lung adenocarcinoma were treated with pemetrexed, carboplatin combined with ibandronate sodium, and those with lung squamous cell carcinoma were treated with paclitaxel liposome for injection or albumin paclitaxel for injection, all patients underwent 2 cycles of chemotherapy. The levels of inflammatory factors such as serum C-reactive protein (CRP), procalcitonin (PCT), tumor necrosis factor (TNF-α), interleukin-6 (IL-6), bone metabolic indexes such as amino intermediate fragment of osteocalcin, amino terminal peptide of type Ⅰ procollagen, carboxy terminal peptide of type Ⅰ collagen β special sequence, bone specific alkaline phosphatase, bone pain score and incidence of adverse reactions were compared before and after chemotherapy.

  Results  After 2 cycles of chemotherapy, the levels of CRP, PCT, TNF-α, IL-6 and the carboxy terminal peptide of type Ⅰ collagen β special sequence were significantly lower than those before chemotherapy, amino intermediate fragment of osteocalcin, amino terminal peptide of type Ⅰ procollagen and bone specific alkaline phosphatase were significantly higher than those before chemotherapy(P < 0.05). The score of bone pain was (15.56±3.89) before chemotherapy and (2.47±1.79) after 2 cycles of chemotherapy, and the score of bone pain after 2 cycles of chemotherapy was significantly lower than that before chemotherapy (P < 0.05). There were 8 cases of fever, 10 cases of nausea, 13 cases of vomiting and 7 cases of bone marrow suppression, with the incidence of adverse reactions of 31.67%.

  Conclusion  Ibanphosphate combined with chemotherapy can significantly reduce the level of serum inflammatory factors in NSCLC patients with bone metastasis, improve the serum bone metabolism indexes, and has good application safety.